COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy

BACKGROUND: Some multiple sclerosis (MS) disease-modifying therapies (DMTs) impair responses to vaccines, emphasizing the importance of understanding COVID-19 vaccine immune responses in people with MS (PwMS) receiving different DMTs. METHODS: This prospective, open-label observational study enrolle...

Descripción completa

Detalles Bibliográficos
Autores principales: Jaber, Aliya, Patel, Meera, Sylvester, Andrew, Yarussi, Mary, Kalina, J. Tamar, Mendoza, Jason P., Avila, Robin L., Tremblay, Matthew A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9931564/
https://www.ncbi.nlm.nih.gov/pubmed/36792812
http://dx.doi.org/10.1007/s40120-023-00448-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9931564/
https://www.ncbi.nlm.nih.gov/pubmed/36792812
http://dx.doi.org/10.1007/s40120-023-00448-x

Ejemplares similares